17.44
price down icon2.68%   -0.48
pre-market  Pre-mercato:  17.40   -0.04   -0.23%
loading
Precedente Chiudi:
$17.92
Aprire:
$18.16
Volume 24 ore:
2.10M
Relative Volume:
1.40
Capitalizzazione di mercato:
$1.55B
Reddito:
$203.45M
Utile/perdita netta:
$-351.45M
Rapporto P/E:
-3.833
EPS:
-4.55
Flusso di cassa netto:
$-369.41M
1 W Prestazione:
-16.99%
1M Prestazione:
-18.50%
6M Prestazione:
+24.66%
1 anno Prestazione:
+138.58%
Intervallo 1D:
Value
$17.36
$18.90
Intervallo di 1 settimana:
Value
$17.36
$21.28
Portata 52W:
Value
$5.12
$25.29

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
Nome
Travere Therapeutics Inc
Name
Telefono
888-969-7879
Name
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Name
Dipendente
385
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
TVTX's Discussions on Twitter

Confronta TVTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TVTX
Travere Therapeutics Inc
17.44 1.55B 203.45M -351.45M -369.41M -4.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-10 Iniziato Cantor Fitzgerald Overweight
2024-10-21 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-09-09 Aggiornamento Guggenheim Neutral → Buy
2024-03-27 Downgrade Guggenheim Buy → Neutral
2023-12-05 Aggiornamento Citigroup Neutral → Buy
2023-11-20 Iniziato Citigroup Neutral
2023-09-22 Downgrade Wells Fargo Overweight → Equal Weight
2023-09-21 Downgrade William Blair Outperform → Mkt Perform
2023-09-06 Ripresa Evercore ISI Outperform
2023-07-21 Iniziato JP Morgan Overweight
2023-06-07 Ripresa Piper Sandler Neutral
2023-05-22 Iniziato TD Cowen Outperform
2023-05-05 Aggiornamento Bryan Garnier Sell → Neutral
2023-03-01 Iniziato Guggenheim Buy
2023-02-21 Aggiornamento Wedbush Neutral → Outperform
2022-12-14 Iniziato Stifel Hold
2022-12-05 Iniziato Wells Fargo Overweight
2022-09-21 Iniziato Bryan Garnier Sell
2022-07-14 Ripresa Canaccord Genuity Buy
2022-03-31 Iniziato Piper Sandler Overweight
2022-02-28 Iniziato H.C. Wainwright Buy
2021-05-26 Downgrade Wedbush Outperform → Neutral
Mostra tutto

Travere Therapeutics Inc Borsa (TVTX) Ultime notizie

pulisher
Apr 01, 2025

The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts - Benzinga

Apr 01, 2025
pulisher
Mar 31, 2025

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - BioSpace

Mar 31, 2025
pulisher
Mar 26, 2025

Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey

Mar 26, 2025
pulisher
Mar 26, 2025

10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey

Mar 26, 2025
pulisher
Mar 26, 2025

Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights - Yahoo Finance

Mar 26, 2025
pulisher
Mar 23, 2025

When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com

Mar 23, 2025
pulisher
Mar 18, 2025

Travere seeks FDA approval for potential FSGS treatment By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 17, 2025

Travere rises on co's marketing application for kidney disease drug - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Travere seeks FDA approval for potential FSGS treatment - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Travere Therapeutics Submits sNDA for FILSPARI as Potential First FDA-Approved Treatment for FSGS - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: First-Ever FSGS Treatment Could Get FDA Green LightFILSPARI Shows Superior Results - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

High Growth Tech Stocks In The US With Promising Potential - Simply Wall St

Mar 14, 2025
pulisher
Mar 13, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 13, 2025
pulisher
Mar 12, 2025

US Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Travere Therapeutics Expands Team with 77,200 Shares in Strategic Equity Grants - Stock Titan

Mar 12, 2025
pulisher
Mar 11, 2025

Travere Therapeutics at Leerink Conference: Filspari’s Promising Path - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Focal Segmental Glomerulosclerosis Treatment Market Size - openPR

Mar 11, 2025
pulisher
Mar 11, 2025

Is Eli Lilly Stock a Buy? - The Globe and Mail

Mar 11, 2025
pulisher
Mar 09, 2025

Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN

Mar 09, 2025
pulisher
Mar 08, 2025

What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - GuruFocus.com

Mar 08, 2025
pulisher
Mar 07, 2025

Travere Therapeutics: Tricky Outlook Gives Me Pause For ThoughtDowngrade - Seeking Alpha

Mar 07, 2025
pulisher
Mar 02, 2025

When the Price of (TVTX) Talks, People Listen - Stock Traders Daily

Mar 02, 2025
pulisher
Mar 01, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $44.00 - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Ieq Capital LLC - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $35.00 at Citigroup - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Q1 EPS Estimate for Travere Therapeutics Lowered by Analyst - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Impax Asset Management Group plc Purchases New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Mirum Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 25, 2025

Travere Therapeutics' (TVTX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Feb 25, 2025
pulisher
Feb 24, 2025

Analyst Expectations For Travere Therapeutics's Future - Benzinga

Feb 24, 2025
pulisher
Feb 24, 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Citi raises Travere Therapeutics price target to $35, maintains buy By Investing.com - Investing.com Canada

Feb 24, 2025
pulisher
Feb 24, 2025

Citi raises Travere Therapeutics price target to $35, maintains buy - Investing.com India

Feb 24, 2025
pulisher
Feb 23, 2025

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug - MSN

Feb 23, 2025
pulisher
Feb 23, 2025

Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 - Insider Monkey

Feb 23, 2025
pulisher
Feb 22, 2025

Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance

Feb 22, 2025
pulisher
Feb 22, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 22, 2025
pulisher
Feb 22, 2025

Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Feb 22, 2025
pulisher
Feb 21, 2025

Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks

Feb 21, 2025
pulisher
Feb 21, 2025

US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 21, 2025
pulisher
Feb 21, 2025

Travere therapeutics chief medical officer sells $60k in stock - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... By GuruFocus - Investing.com Canada

Feb 21, 2025

Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Capitalizzazione:     |  Volume (24 ore):